Cost-effectiveness of enoxaparin as thromboprophylaxis in acutely III medical patients in Spain

Value in Health

Volumn 6, Issue 2, 2003, Pages 126-136

  Nuijten, M J C ^a,f   Antonanzas Villar F ^b   Kosa, J ^a   Nadipelli, V ^c   Rubio Terres C ^d   Suarez, C ^e  

^a MEDTAP International   (Netherlands)

^b SOIKOS   (Spain)

^c SANOFI   (France)

^d Aventis Pharma   (Spain)

^e HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^f NONE   (Netherlands)

Author keywords

Cost effectiveness; Enoxaparin; Markov model; Spain

Indexed keywords

ENOXAPARIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONSULTATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; CRITICAL ILLNESS; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HOSPITALIZATION; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NURSING; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK MANAGEMENT; SIDE EFFECT; SPAIN; TREATMENT OUTCOME; VARICOSIS; VEIN THROMBOSIS;

EID: 0344838609     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4733.2003.00210.x     Document Type: Article

References (23)

1. Ruiz J, Alberich P, Blanquer J, et al. Normativas SEPAR: normative for the prophylaxis of the venous thrombolism disease. Arch Bronconeumol 1996;32:1665-70.
2. Gabriel F, Labiós M, Brasó JV. Deep venous thrombosis: present and future. Med Clin (Barc) 2000;114:584-96.
3. Hospital Morbidity Survey 1997. Madrid: National Institute of Statistics, 2000.
4. Deaths by Their Cause 1996. Madrid: National Institute of Statistics, 1999.
5. Rosendo A, Fernández D, Lucio R, Latorre J. Epidemiología. In: Güell J, Rosendo A, eds., Venous Thromboembolic Disease: Post-Thrombotic Syndrome. Barcelona: Edika Med, 1995.
6. Moser K, Fedullo P, Litte JJ, Crawford R. Frequent asymptomatic pulmonary embolism in patients with deep venous thrombosis. JAMA 1994;271: 223-5.
7. López-Beret P, Pinto JM, Romero A, Orgaz A, et al. Systematic study of occult pulmonary thromboembolism in patients with deep thrombosis. J Vasc Surg 2001;33:515-21.
8. Uresandi F, Muñoz F, Antoñana MA, et al. Deep venous thrombosis in pulmonary embolism: prevalence and assessment of its clinic semiology. Arch Bronconeumol 1992;28:371-4.
9. Rubinstein I, Murray D, Hoffstein V. Fatal pulmonary embolism in hospitalised patients. Arch Intern Med 1988;148:1425-6.
10. Oster G, Tuden R, Colditz G. Prevention of venous thromboembolism after general surgery: cost-effectiveness analysis of alternative approaches to prophylaxis. Am J Med 1987;82:889-99.
11. Goldhaber SZ, De Rosa M, Visani L. International Cooperative Pulmonary Embolism Registry detects high mortality rate. Circulation 1997;96(Suppl I): 151-159.
12. Kakkar V. Low molecular weight heparins: prophylaxis of venous thromboembolism in surgical patients. Semin Hematol 1997;34:9-19.
13. Prandoni P, Lensing A, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;25:1-7.
14. Grau E, Real E, Medrano J, et al. Recurrent venous thromboembolism in a Spanish population: incidence, risk factors, and management in a hospital setting. Thromb Res 1999;96:335-41.
15. Bergqvist D, Jendteg S, Johansen L, et al. Cost of long-term complications of deep venous thrombosis of the lower extremities: an analysis of a defined patient population in Sweden. Ann Intern Med 1997;126:454-7.
16. Immelman EJ, Jeffry PC. The postphlebitic syndrome: pathophysiology, prevention and management. Clin Chest Med 1994;6:537-50.
17. Monreal M, Martorell A, Callejas JM, et al. Venographuc assessment of deep vein thrombosis and risk of developing post-thrombotic syndrome: a prospective study. J Intern Med 1993;233:233-8.
18. Samama MM, Cohen AT, Damon JY, et al. A comparion of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients: prophylaxis in medical patients with enoxaparin study group. N Engl J Med 1999;341:793-800.
19. Weinstein M, Fineberg H. Clinical Decision Analysis. London: Saunders, 1980.
20. Holloway CA. Decision Making under Uncertainty Models and Choices. Englewood Cliffs (NJ): Prentice Hall, 1979.
21. Nuijten MJC. Data management in modeling studies: the selection of data sources. Pharmacoeconomics 1998;3:305-16.
22. Pechevis M, Detournay B, Pribil C, et al. Economic evaluation of enoxaparin vs placebo for the prevention of venous thromboembolism in acutely ill medical patients. Value Health 2000;3:389-96.
23. Lloyd AC, Anderson PM, Quinlan DJ, Bearne A. Economic evaluation of the use of enoxaparin for thromboprophylaxis in acutely ill medical patients. J Med Econ 2001;4:99-113.